title: Survey of Victorian ophthalmologists who use ranibizumab to treat age-related macular degeneration: to identify current practice and modifiable risk factors relevant to post-injection endophthalmitis.
authors.affiliation: Royal Victorian Eye and Ear Hospital, Melbourne, Victoria, Australia.
authors.forename: Danielle A
authors.initials: DA
authors.lastname: Buck
authors.forename: Rosie
authors.initials: R
authors.lastname: Dawkins
authors.forename: Ryo
authors.initials: R
authors.lastname: Kawasaki
authors.forename: Sukhpal S
authors.initials: SS
authors.lastname: Sandhu
authors.forename: Penelope J
authors.initials: PJ
authors.lastname: Allen
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D009877:Endophthalmitis / Q000209:etiology / Q000517:prevention & control*; D006306:Health Surveys; D006801:Humans; D058449:Intravitreal Injections; D009885:Ophthalmology / Q000706:statistics & numerical data*; D011183:Postoperative Complications / Q000517:prevention & control*; D010818:Practice Patterns, Physicians' / Q000706:statistics & numerical data*; D000069579:Ranibizumab; D012307:Risk Factors; D011795:Surveys and Questionnaires; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014739:Victoria; D057135:Wet Macular Degeneration / Q000188:drug therapy*
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000069579:Ranibizumab